Abeona Therapeutics (NASDAQ:ABEO) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) from a sell rating to a hold rating in a research report sent to investors on Monday morning.

A number of other equities research analysts have also recently issued reports on ABEO. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday. Oppenheimer started coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They set an "outperform" rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.50.

Abeona Therapeutics Stock Down 1.3 %

Shares of ABEO stock traded down $0.07 on Monday, hitting $4.98. The company's stock had a trading volume of 347,179 shares, compared to its average volume of 337,142. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock has a market capitalization of $216.27 million, a price-to-earnings ratio of -1.85 and a beta of 1.79. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The firm's fifty day moving average price is $5.42 and its 200-day moving average price is $5.81.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.19. Research analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors have recently modified their holdings of the business. Twinbeech Capital LP acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth approximately $58,000. Squarepoint Ops LLC acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth about $67,000. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter valued at about $84,000. Oxford Asset Management LLP acquired a new stake in Abeona Therapeutics in the 4th quarter valued at about $118,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Abeona Therapeutics during the third quarter worth about $151,000. Institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.